HOOKIPA to Participate in the Sidoti Micro-Cap Virtual Conference
02 nov. 2022 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Nov. 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
20 oct. 2022 07h00 HE
|
HOOKIPA Pharma Inc.
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive $25 million in upfront cash as well as potential...
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
07 sept. 2022 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...
HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates
11 août 2022 07h00 HE
|
HOOKIPA Pharma Inc.
HB-200 Phase 1 data presented at ASCO met all endpoints in heavily pre-treated head and neck cancer patients; Phase 2 study underwayUS Food and Drug Administration accepted HOOKIPA’s Investigational...
HOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022
04 août 2022 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Aug. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...
FDA accepts HOOKIPA’s Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer
25 juil. 2022 08h00 HE
|
HOOKIPA Pharma Inc.
Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase 1/2 trial to commence by early 2023Drug Master File (DMF) accepted to support future FDA submissions ...
HOOKIPA Announces Executive Leadership Changes
21 juin 2022 09h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, June 21, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA to Participate in the JMP Securities Life Sciences Conference
09 juin 2022 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, June 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
05 juin 2022 09h00 HE
|
HOOKIPA Pharma Inc.
Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapyPhase 2 to proceed with alternating...
Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium
03 juin 2022 07h00 HE
|
HOOKIPA Pharma Inc.
Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting Alternating 2-vector...